Cart
sales@molnova.com
Cinpanemab
CAS No. 2094516-02-4
Cinpanemab( —— )
Catalog No. M36746 CAS No. 2094516-02-4
Cinpanemab (BIIB054) is a novel human monoclonal antibody with affinity for alpha-synuclein residues 1-10. Cinpanemab can be used to study Parkinson's disease and related diseases.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 490 | In Stock |
|
| 10MG | 787 | In Stock |
|
| 25MG | 1169 | In Stock |
|
| 50MG | 1535 | In Stock |
|
| 100MG | 2074 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCinpanemab
-
NoteResearch use only, not for human use.
-
Brief DescriptionCinpanemab (BIIB054) is a novel human monoclonal antibody with affinity for alpha-synuclein residues 1-10. Cinpanemab can be used to study Parkinson's disease and related diseases.
-
DescriptionCinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease.
-
In Vitro——
-
In VivoAnimal Model:C57BL/6JRccHsd WT mice, transgenic M83 mice expressing human α-syn A53T, and transgenic bacterial artificial chromosome mice expressing human α-syn A53T were anesthetized and stereotaxically injected with α-syn preformed fibrils (PFFs) into the right forebrain Dosage:30 mg/kg Administration:Intraperitoneal (i.p.) injections 2-3 times prior to α-syn PFF injection and weekly post-injection until time of sacrifice Result:Attenuated the spreading of α-syn pathology, rescued motor impairments, and reduced the loss of dopamine transporter density in dopaminergic terminals in striatum.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2094516-02-4
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Lang AE, et, al. Trial of Cinpanemab in Early Parkinson's Disease. N Engl J Med. 2022 Aug 4;387(5):408-420. ?
molnova catalog
related products
-
Sarafotoxin B|SARAFO...
Sarafotoxin S6b is a vasoconstrictor peptide, and a non-selective endothelin receptor agonist. Sarafotoxin S6b can induce contraction in isolated human coronary arteries , the Ki values of Coronary artery, Saphenous vein and Coronary artery are 0.27, 0.55 and 19.5 nM, respectively.
-
Bim BH3, Peptide IV ...
Bim BH3, Peptide IV TFA is a 26-site residue of BH3 protein Bim, belonging to the pro-apoptotic group of bcl-2 protein family.
-
Alpidem
Alpidem is an anxiolytic drug from the imidazopyridine family. Alpidem does not produce sedative effects at normal doses, and is instead used specifically for the treatment of anxiety. Alpidem has nanomolar binding affinity for both the central benzodiaze
